Fig. 3: Biomarkers during ruxolitinib treatment. | Leukemia

Fig. 3: Biomarkers during ruxolitinib treatment.

From: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

Fig. 3

C-reactive protein (panel A), interleukin-6 (panel B), and ferritin (panel C) levels over 28 days treatment period in the intention-to-treat population (N = 16) with corresponding numbers of patients observed at each assessment. Note that the y axes are log-scale. Asterisks show significance level of p value obtained in two-sided Wilcoxon-Mann–Whitney test for a given assessment when compared to baseline distribution (*P < 0.05; **P < 0.01; ***P < 0.001). Please note, that these values have not been corrected for multiple testing.

Back to article page